Clinical trial
Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
NCT02903771 is registered in ClinicalTrials.gov with Kazia Therapeutics Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
- Lead sponsor
- Kazia Therapeutics Limited
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 5, 2016
- Completion date
- March 24, 2020
- Enrollment
- 32 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.